AU2001286889A1 - Process and intermediates for preparing retroviral protease inhibitors - Google Patents

Process and intermediates for preparing retroviral protease inhibitors

Info

Publication number
AU2001286889A1
AU2001286889A1 AU2001286889A AU8688901A AU2001286889A1 AU 2001286889 A1 AU2001286889 A1 AU 2001286889A1 AU 2001286889 A AU2001286889 A AU 2001286889A AU 8688901 A AU8688901 A AU 8688901A AU 2001286889 A1 AU2001286889 A1 AU 2001286889A1
Authority
AU
Australia
Prior art keywords
intermediates
protease inhibitors
retroviral protease
preparing retroviral
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001286889A
Inventor
Sanjay R. Chemburkar
Ketan M. Patel
Harry O. Spiwek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24614772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2001286889(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of AU2001286889A1 publication Critical patent/AU2001286889A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • AIDS & HIV (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The instant invention provides processes and intermediates employed in the synthesis of ((2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2S-(1-tetrahydropyrimid-2-onyl)-3-methyl-butanoyl)amino-1,6-diphenylhexane and analogs thereof.
AU2001286889A 2000-08-31 2001-08-29 Process and intermediates for preparing retroviral protease inhibitors Abandoned AU2001286889A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65191900A 2000-08-31 2000-08-31
US09651919 2000-08-31
PCT/US2001/026898 WO2002018349A2 (en) 2000-08-31 2001-08-29 Process and intermediates for preparing retroviral protease inhibitors

Publications (1)

Publication Number Publication Date
AU2001286889A1 true AU2001286889A1 (en) 2002-03-13

Family

ID=24614772

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001286889A Abandoned AU2001286889A1 (en) 2000-08-31 2001-08-29 Process and intermediates for preparing retroviral protease inhibitors

Country Status (17)

Country Link
EP (1) EP1313712B1 (en)
JP (1) JP5021141B2 (en)
KR (1) KR100806533B1 (en)
CN (1) CN1264823C (en)
AT (1) ATE361913T1 (en)
AU (1) AU2001286889A1 (en)
BR (1) BR0108146A (en)
CA (2) CA2416955C (en)
CY (1) CY1106738T1 (en)
DE (1) DE60128367T2 (en)
DK (1) DK1313712T3 (en)
ES (1) ES2284684T3 (en)
HK (1) HK1057040A1 (en)
IL (1) IL153436A0 (en)
MX (1) MXPA03001751A (en)
PT (1) PT1313712E (en)
WO (1) WO2002018349A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2378669T3 (en) * 2003-12-11 2012-04-16 Abbott Laboratories HIV protease inhibitor compounds
CN100358521C (en) * 2004-12-28 2008-01-02 哈尔滨欧替药业股份有限公司 Suppository of Metronidazole and preparation technique
CN103910634B (en) * 2012-12-29 2018-04-27 广东东阳光药业有限公司 The preparation method of sitagliptin intermediate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds

Also Published As

Publication number Publication date
BR0108146A (en) 2004-01-06
CA2731273A1 (en) 2002-03-07
CA2416955A1 (en) 2002-03-07
DE60128367T2 (en) 2008-01-10
WO2002018349A3 (en) 2002-05-10
EP1313712B1 (en) 2007-05-09
WO2002018349A2 (en) 2002-03-07
DE60128367D1 (en) 2007-06-21
CN1264823C (en) 2006-07-19
PT1313712E (en) 2007-07-25
CY1106738T1 (en) 2012-05-23
HK1057040A1 (en) 2004-03-12
ES2284684T3 (en) 2007-11-16
CA2416955C (en) 2011-04-26
CA2731273C (en) 2013-10-15
KR100806533B1 (en) 2008-02-25
MXPA03001751A (en) 2003-09-10
JP5021141B2 (en) 2012-09-05
JP2004507528A (en) 2004-03-11
DK1313712T3 (en) 2007-09-10
IL153436A0 (en) 2003-07-06
EP1313712A2 (en) 2003-05-28
ATE361913T1 (en) 2007-06-15
CN1449388A (en) 2003-10-15
KR20030061787A (en) 2003-07-22

Similar Documents

Publication Publication Date Title
PL372799A1 (en) New compounds
AP2003002916A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
IS2600B (en) New triazole pyrimidine compounds
IL138113A0 (en) Synthesis of epothilones, intermediates thereto and analogues thereof
AU1613601A (en) Cleaning process which uses ultrasonic waves
MY113489A (en) Reversible protease inhibitors
IL149005A0 (en) Hexahydrofuro-2', 3-bifuran-3-yl-n-{3'(1, 3-benzodioxol-5-ylsulfonyl) (isobutyl) amino-1-benzyl-2-hydroxypropyl} carbamate as restroviral protease inhibitor
HK1060729A1 (en) Inhibitors of cruzipain and other cysteine proteases
AU1613801A (en) Cleaning process which uses ultrasonic waves
TW200517374A (en) Cyclohexanecarboxylic acids
BG104885A (en) Novel heterocyclically substituted amides with cysteine protease-inhibiting effect
YU61103A (en) Processes for the production of substituted 2- (2-pyridylmethyl)sulfinyl-1h-benzimidazoles
AU2924699A (en) Tryptase inhibitors
NZ331875A (en) Asymmetric synthesis of R-alpha-propyl-piperonyl amine and its analogs
AU7903400A (en) Selective inhibitors of the urokinase plasminogene activators
PL325954A1 (en) Guanidinic protease inhibitors
WO2004046293A8 (en) Amphoteric fluorescent whitening agents
AU2001286889A1 (en) Process and intermediates for preparing retroviral protease inhibitors
WO2001000577A3 (en) Preparation of substituted piperidin-4-ones
AU2002326925A1 (en) Process for preparing protease inhibitor intermediates
HUP0105439A2 (en) Process for the synthesis of hiv protease inhibitors
DE69827614D1 (en) quinoxalinediones
MXPA03009723A (en) Processes and intermediates for preparing benzyl substituted epoxides.
PL359727A1 (en) Crystalline pharmaceutical
AU4662900A (en) 4-cyano-3-hydroxy butanoyl hydrazines, derivatives and process for the preparation thereof